The fact that we found that neutralizing FasL carried by MPs prevented vascular dysfunction supports of the hypothesis of an interaction between FasL from MetS MPs with Fas from the vessel wall of the treated/injected mouse. The gene discussed is FAS; the disease is metabolic syndrome.